Noubar Afeyan

Noubar Afeyan has an estimated net worth of $5.4 Billion. This is based on reported shares across multiple companies, which include Sana Biotechnology, Inc., Moderna, Inc., Kaleido Biosciences, Inc., TETRAPHASE PHARMACEUTICALS INC, AGIOS PHARMACEUTICALS INC, BG Medicine, Inc., BIND Therapeutics, Inc, Receptos, Inc., Omega Therapeutics, Inc., Seres Therapeutics, Inc., Editas Medicine, Inc., TransMedics Group, Inc., Quanterix Corp, Foghorn Therapeutics Inc., Denali Therapeutics Inc., CONCERT PHARMACEUTICALS, INC., SELECTA BIOSCIENCES INC, Rubius Therapeutics, Inc., Syros Pharmaceuticals, Inc., Eleven Biotherapeutics, Inc., ANTIGENICS INC /DE/, Codiak BioSciences, Inc., T2 Biosystems, Inc., Axcella Health Inc., Sigilon Therapeutics, Inc., Evelo Biosciences, Inc., HELICOS BIOSCIENCES CORP, ACCELERON PHARMA INC, and Generate Biomedicines, Inc..

2019 was Noubar Afeyan's most active year for acquiring shares with 37 total transactions. Noubar Afeyan's most active month to acquire stocks was the month of January. 2024 was Noubar Afeyan's most active year for disposing of shares, totalling 128 transactions. Noubar Afeyan's most active month to dispose stocks was the month of April. 2026 saw Noubar Afeyan paying a total of $164,999,766.73 for 79,856,284 shares, this is the most they've acquired in one year. In 2021 Noubar Afeyan cashed out on 129,933,660 shares for a total of $1,442,141,068.73, their largest year based on trade value.